MS is a chronic, immune-mediated inflammatory and neurodegenerative disease of the central nervous system (CNS), with an etiology that is not yet fully understood. The prevalence of MS is highest where environmental supplies of vitamin D are lowest. It is well recognized that the active hormonal form of vitamin D, 1,25-dihydroxyvitamin D (1,25-(OH) 2 D), is a natural immunoregulator with anti-inflammatory action. The mechanism by which vitamin D nutrition is thought to influence MS involves paracrine or autocrine metabolism of 25OHD by cells expressing the enzyme 1a-OHase in peripheral tissues involved in immune and neural function. Administration of the active metabolite 1,25-(OH) 2 D in mice and rats with experimental allergic encephalomyelitis (EAE, an animal model of MS) not only prevented, but also reduced disease activity. 1,25-(OH) 2 D alters dendritic cell and T-cell function and regulates macrophages in EAE. Interestingly, 1,25-(OH) 2 D is thought to be operating on CNS constituent cells as well. Vitamin D deficiency is caused by insufficient sunlight exposure or low dietary vitamin D 3 intake. Subtle defects in vitamin D metabolism, including genetic polymorphisms related to vitamin D, might possibly be involved as well. Optimal 25OHD serum concentrations, throughout the year, may be beneficial for patients with MS, both to obtain immune-mediated suppression of disease activity, and also to decrease disease-related complications, including increased bone resorption, fractures, and muscle weakness.
Introduction
Multiple sclerosis (MS) is a slowly progressive, often disabling disease of the central nervous system (CNS), characterized by disseminated patches of demyelination in the brain and spinal cord. This disease results in multiple and varied neurologic symptoms and signs, usually with exacerbations and remissions at the onset: relapsing-remitting (RR) MS, followed in later years by a more chronic progressive course: secondary progressive (SP) MS. A primary progressive form (PP) of MS is also recognized. Women are affected more often than men. Age at onset of the clinical symptoms is typically between 20 and 40 y. It is uncertain whether MS is a single disease or whether the varying clinical patterns, for example, the relapsing and progressive forms, represent distinct entities (Noseworthy, 1999) . In some MS patients (10-20%), the course of the disease can be classified as benign as they do not develop the characteristic disabilities (McAlpine, 1961; Ramsaransing et al, 2001) . Plaques of demyelination, with perivascular inflammation and destruction of oligodendroglia, preceded by violation of the bloodbrain barrier (BBB), are scattered throughout the white matter of the CNS. Apart from demyelination, axonal damage occurs in early stages of MS (Trapp et al, 1999; Bjartmar et al, 2003) . Within one person, recent inflamed and more chronic lesions may coexist. Between MS patients, four basic patterns of neuropathological lesion characteristics suggest distinct, divergent disease mechanisms (Lucchinetti et al, 1996) .
A role for vitamin D in MS has been suggested (Goldberg, 1974a, b; Hayes et al, 1997; Hayes, 2000) . The key questions concerning vitamin D are, one: is MS prevented by an adequate supply of vitamin D 3 , two: is MS aggravated by vitamin D deficiency, three: is MS aggravated by a vitamin D metabolic disorder, including four: a genetic vitamin Drelated disorder?
Etiological factors of MS
The etiology of MS is unknown. It is regarded as a complex multicausal disease. The etiological factors comprise (a) genetic factors, (b) dysfunction of the immune system (autoimmunity), and (c) environmental factors.
An increased family incidence and association with certain HLA allotypes suggests genetic susceptibility (Ebers & Sadovnick, 1994) . The genetic epidemiology indicates that MS is not a single-gene disorder (Ebers, 1994; Compston, 1997; Noseworthy, 1999) .
Autoimmune responses to myelin components may play an important role in the initiation of MS. The autoimmune character of MS is supported by the presence of numerous T lymphocytes in MS lesions and various deviating immune parameters for MS patients (Lucchinetti et al, 1996) . Furthermore, the autoimmune animal model for MS, experimental allergic encephalomyelitis (EAE), has supported the role of autoimmunity in the pathogenesis of MS.
Among the postulated environmental etiological factors for MS is infection by a latent virus, possibly by a human herpes virus or retrovirus, in which viral activation and expression trigger a secondary response. However, no virus has yet been identified that causes MS (Genain & Hauser, 1997; Monteyne et al, 1998) . Other environmental factors, possibly contributing to susceptibility for MS, are sunlight and nutrition (Agranoff & Goldberg, 1974; Alter et al, 1974; Goldberg, 1974a, b; Murrell et al, 1991; Esparza et al, 1995; Hutter & Laing, 1996; Hayes et al, 1997; Lauer, 1997; Van Noort & Amor, 1998) . The vast amount of literature on nutrition and MS indicates that food intake may be an influencing factor determining the disease susceptibility. For example, the intake of grain (high in phytic acid) or meat, fat, and milk from animals correlated positively with the prevalence of MS (Swank et al, 1952; Goldberg, 1974a; Murrell et al, 1991; Esparza et al, 1995) . Conversely, the intake of rice (low in phytic acid), fish, oil, skim milk, vegetables, and fruit correlated negatively with the prevalence of MS (Swank, 1953; Goldberg, 1974a; Lauer, 1997) . Both phytic acid and fat may influence the bioavailability of vitamin D metabolites. Phytic acid may reduce the absorption of calcium in the gut (Mellanby, 1950) . Obesity has been associated with vitamin D deficiency (Wortsman et al, 2000) . Unfortunately, conclusive studies on the bioavailability of vitamin D 3 are rare as no validated methods for assessing the bioavailability are available (Van den Berg, 1997 ). An association has been reported in Norway between the relatively low risk of MS along its Atlantic coast and the relatively high dietary intake of fish oil, a rich source of vitamin D 3 (Swank et al, 1952; Goldberg, 1974a; Hayes et al, 1997) .
Vitamin D metabolism
Vitamin D Vitamin D 3 , a lipid-soluble vitamin, is produced by sunlight in the skin, and can also be provided by the diet. It is a precursor of the metabolic active hormone 1,25-(OH) 2 D. Sunlight has long been recognized as a major provider of vitamin D 3 for humans. Radiation in the UV-B (290-315 nm) portion of the solar spectrum photolyzes 7-dehydrocholesterol (provitamin D 3 ) in the skin to previtamin D 3 , which, in turn, is converted by a thermal process to vitamin D 3 (Holick, 1987; Webb & Holick, 1988) . The synthesis of vitamin D 3 in the skin is self-regulating (Webb et al, 1989) . Excessive exposure to sunlight causes a photodegradation of previtamin D 3 and vitamin D 3 to prevent vitamin D 3 intoxication (Clemens et al, 1982; Matsuoka et al, 1987) .
In addition to the production in the skin, vitamin D is supplied by food in two forms; vitamin D 2 (ergocalciferol, activated ergosterol), found in irradiated yeast, and vitamin D 3 (cholecalciferol), found in fish liver oils and fatty fish, including herring, mackerel, and sardines. The natural human diet can only be considered as a secondary source of the vitamin, when there is enough exposure to sunlight (Fraser, 1995; Vieth, 1999; Heaney et al, 2003a) . However, in winter when UV-B in sunlight is limited, or when sunlight exposure is not adequate, dietary factors become of vital importance and dietary compensation should occur.
Vitamin D 3 is biologically inactive. It is either stored in fat or converted by 25-hydroxylase (25-OHase) enzyme in the liver to 25OHD. Interestingly, the presence of 25-OHase activity has also been demonstrated outside the liver in kidney, in keratinocytes in skin, and in parathyroid cells (Lehmann et al, 1999; Gascon-Barre et al, 2001; Correa et al, 2002) .
25OHD
25OHD is the major circulating form of vitamin D. The serum half-life of 25OHD is approximately 10 days to 3 weeks. Serum 25OHD concentration is the indicator of the vitamin D status, and provides a good reflection of cumulative effects of exposure to sunlight and dietary intake of vitamin D (Food and Nutrition Board (FNB), Institute of Medicine, 1997). Its concentration is used as a diagnostic criterion of vitamin D deficiency. 25OHD is either stored in the liver or further converted by the enzyme 1a-hydroxylase (1a-OHase) to 1,25-(OH) 2 D in the kidney, as well as in extra-renal tissues, including the brain (cerebellum, cerebral cortex) and lymph nodes (Hewison et al, 2000; Zehnder et al, 2001) .
Renal 1,25-(OH) 2 D and extra-renal 1,25-(OH) 2 D 1,25-(OH) 2 D is the hormonally active form of vitamin D. Accumulating reports have provided evidence that 1,25-(OH) 2 D is a pleiotropic hormone influencing a plethora of biological actions, including regulation of calcium homeostasis, control of cell differentiation and maturation, and modification of immune responses (Casteels et al, 1995; Cantorna et al, 1996; Hayes et al, 1997; Verstuyf et al, 1998; Brown et al, 1999; Hewison et al, 2000; Hayes, 2000; Overbergh et al, 2000; Mathieu et al, 2001; Garcion et al, 2002) . In addition, 1,25-(OH) 2 D induces cell death, making the hormone of potential interest in the management of breast, prostate, and colon cancer, including brain tumors Garcion et al, 2002) . The serum half-life of 1,25-(OH) 2 D is 4-6 h (Kumar, 1986) . The renal 1a-hydroxylation of 25OHD to 1,25-(OH) 2 D is highly regulated by the serum concentrations of parathyroid hormone (PTH), calcium, and phosphate (Lips, 2001 ). Owing to its relatively short serum half-life and the tight regulation of the production of 1,25-(OH) 2 D, it has not been proven to be a valuable marker for vitamin D deficiency, adequacy, or excess (FNB, Institute of Medicine, 1997) .
It is now acknowledged that a wide variety of extra-renal cells can produce 1,25-(OH) 2 D from 25OHD by the enzyme 1a-OHase in vitro, including activated macrophages, keratinocytes, and CNS cells (neurons and microglial cells) (Adams et al, 1985; Pillai et al, 1987; Neveu et al, 1994) . The extrarenal production of 1,25-(OH) 2 D is not regulated in the same way as its renal production. The relationship between expression of 1a-OHase activity by 1,25-(OH) 2 D in a particular tissue probably involves two specific mechanisms, the first of these being substrate access, and the second being auto-regulation of 1a-OHase activity by 1,25-(OH) 2 D itself (Hewison et al, 2000) .
Exceptional levels of circulating 1,25-(OH) 2 D are found in several clinical conditions. Lower levels have been found in severe vitamin D deficiency (Lips et al, 1982 (Lips et al, , 1988 Bouillon et al, 1987) , as well as in inherited vitamin D metabolic disorders and chronic renal failure. Higher levels, caused by excessive extra-renal production, have been observed in sarcoidosis, tuberculosis, or malignant lymphoproliferation . The gene encoding 1a-OHase is located on chromosome 12q13 and abnormal gene expression is the cause of hereditary pseudovitamin D-deficiency rickets (PDDR) (St-Arnaud et al, 1997) .
Vitamin D catabolism
Ultimately, 25OHD and 1,25-(OH) 2 D are metabolized by 24-hydroxylase (24-OHase), an enzyme induced by 1,25-(OH) 2 D itself to control its own levels in circulation (Brown et al, 1999) . Finally, calcitroic acid is the major excretory form (Esvelt and De Luca, 1981) .
Vitamin D transport and function
Vitamin D-binding protein (DBP) Vitamin D-binding protein (DBP) is a serum globulin, which is mainly produced in the liver. DBP transports vitamin D metabolites to a large number of target organs. Under normal physiological conditions, most of the circulating vitamin D metabolites are bound to DBP and albumin. DBP helps to regulate the bioavailability of 1,25-(OH) 2 D, as it buffers the levels of the free metabolites and thus affords a degree of protection against short-term seasonally or dietary induced fluctuations (White & Cooke, 2000) . The DBP gene locus 4q12 is among the most polymorphic known.
Vitamin D receptor (VDR)
When entering a target cell, 1,25-(OH) 2 D dissociates from DBP, diffuses across the plasma membrane, connects to the vitamin D receptor (VDR) and shuttles between the cytoplasm and the nucleus (nuclear VDR, nVDR). Cellular action only follows after binding of 1,25-(OH) 2 D by the nVDR in the target cell. The gene encoding the VDR is located on chromosome 12q14 and has several common allelic variants (Zmuda et al, 2000) .
The nVDR is a member of the nuclear steroid, retinoid, and thyroid hormone receptor superfamily, acts as a ligandactivated transcription regulator, and 1,25-(OH) 2 D is a ligand. The activated VDR dimerizes with another nuclear receptor, the retinoic acid receptor (RXR). The heterodimer RXR/VDR/1,25-(OH) 2 D binds to a vitamin D responsive element (VDRE), a specific sequence of DNA, in the promoter region of target genes, regulated by 1,25-(OH) 2 D. Upon binding to the VDRE, the heterodimer RXR/VDR/1,25-(OH) 2 D activates or suppresses gene transcription, whereby synthesis of proteins is induced or repressed. 1,25-(OH) 2 D thus exerts biological actions through VDR-mediated gene expression dependent on the target cell (Brown et al, 1999) . VDR can also form homodimers, of which the functional significance is unknown (Issa et al, 1998) . Efficient transcription requires co-activator or co-repressor proteins (Brown et al, 1999) . For instance, Smad3, a downstream component of the transforming growth factor (TGF)-b signaling pathway, acts as a co-activator of VDR, by potentiating ligandinduced transactivation of the VDR . On the other hand, Smad-7 abrogates this Smad3-mediated VDR potentiation by inhibiting the Smad3-VDR complex. Thus, the interplay between the TGF-b and vitamin D pathways can modulate the VDR transactivation both positively and negatively by involving different Smad proteins . 1,25-(OH) 2 D also mediates rapid responses via a putative membrane-bound receptor of the hormone (Norman et al, 1992 (Pike, 1991) . The VDR has been identified in most nucleated cells of the body, involved in countless physiological functions (Walters, 1992) . VDRcontaining cells, in autoimmune diseases, include b-cells in the pancreas in insulin-dependent diabetes mellitus (IDDM), chondrocytes in the joints in rheumatoid arthritis (RA), and oligodendrocytes in the brain in MS (Casteels et al, 1995; Baas et al, 2000; DeLuca & Cantorna, 2001) . In parallel to oligodendrocytes, other CNS constituent cells (microglia, neurons, and astrocytes) are VDR-expressing cells responding directly to the hormone (Garcion et al, 2002) . The VDR has also been identified in immune-competent cells, including macrophages and activated T-lymphocytes, which implies that 1,25-(OH) 2 D can exert effects on immune functions carried out by these cells (Bhalla et al, 1983; Provvedini et al, 1983) .
Sunlight and vitamin D metabolism
Sunlight and vitamin D 3 production in skin The production of vitamin D 3 in the skin depends on exposure to sunlight. Yet, not all sunlight is intense enough to produce vitamin D 3 in the skin. UV-B irradiance is the result of solar elevation, which in turn relies on three factors -latitude, time of year, and time of day. UV-B irradiance, necessary for vitamin D 3 production, is less when the sun is lower and its path length through the atmosphere becomes longer; additional factors influencing its intensity include cloud cover, the amount of ozone, altitude, reflectivity of the earth's surface, haze (aerosols), and other pollutions. In the tropics, sunlight is able to produce vitamin D 3 in the skin all year round. Outside the tropics at latitudes between 23:51, the sun is never at right angles relative to the earth's surface and the seasonal influence becomes greater. At latitudes higher than around 351, sunlight is not able to produce previtamin D 3 in vitro all year round (Holick, 2002) . In winter, the sun is not only weaker as its elevation is lower, but people also spend less time outdoors and cover their skin with clothing (Webb & Holick, 1988) . If one strives to achieve and maintain an optimal serum 25OHD concentration throughout the year, it is important to know when sunlight is able to produce vitamin D 3 in the skin and how long one needs to stay outdoors to produce a sufficient amount. Matters are being complicated, as UV-B irradiance has become a topic of increasing concern, because of its potential negative effects, including sunburn and skin cancer. Excessive UV-B irradiance needs to be avoided, without losing sight of its positive effect.
The ability to synthesize previtamin D 3 in vitro has been published for a number of cities in the world (Figure 1 ). In Los Angeles, USA, at latitude 33:561NL with an altitude (alt.) at 38 m above sea level, sunlight can produce previtamin D 3 in vitro all year round. In Boston, USA (42:221 NL, alt. 6 m), little if any cutaneous vitamin D 3 production occurs in the four winter months from November to February, no matter how long one stays outdoors and in Edmonton, Canada (53:191 NL, alt. 715 m) the equivalent 'vitamin D winter' lasts 6 months, from October to March (Webb & Holick, 1988) . The influence of season and latitude on the synthesis of previtamin D 3 in vitro in the southern hemisphere was measured in Buenos Aires (34:50 SL1, alt. 20 m), Cape Town (33:58 SL1, alt. 42 m), Johannesburg (26:081 SL, alt. 1694 m) and Ushuaoa (54:481 SL, alt. 16 m) (Holick, 2002) . Only in Ushuaoa (54:481 SL, alt. 16 m) no previtamin D 3 was formed in the 6 winter months April-September. For Europe, no comparable data on cutaneous vitamin D 3 production have been reported, except for Bergen in Norway (60:171 NL, alt. 50 m). In Bergen the 'vitamin D winter' lasted 6 months, from October to March, but in the other months of the year the previtamin D 3 formation per month is less than in Edmonton and the hours of UV-B per day are also fewer (Holick, 2002) .
In the United States the vitamin D intake is much higher than in Europe, due to fortification of milk with 10 mg (400 IU) vitamin D per quart (Norman, 2000) . Currently, in Europe, which is, by the way, much further away from the equator than the United States, milk is not fortified with vitamin D and recommended nutritional supplementation with vitamin D differs from country to country.
During the 'vitamin D winter', the body is dependent on its vitamin D 3 stores or on dietary intake from natural sources, food fortified with vitamin D, or supplements. As vitamin D 3 barely occurs naturally in food, and food in most countries is not fortified with vitamin D, dietary supplementation with the vitamin may be necessary for certain groups in the 'vitamin D winter' to maintain an optimal 25OHD serum level throughout the year.
Sunlight and 25OHD
The approximate normal range for serum 25OHD values is 25-130 nmol/l (Feldman et al, 1997) . Currently, there is no consensus on what represents an optimal serum 25OHD concentration. An increasing number of reports is available on 25OHD serum levels both in healthy and unhealthy populations, from which it has become apparent that serum 25OHD levels vary from winter to summer, with lower levels in winter (Stamp, 1975; Bouillon et al, 1987; Lips et al, 1988 : McKenna, 1992 Scharla et al, 1996; Scharla, 1998 ). Here we focus on two of these reports (Bouillon et al, 1987; Scharla, 1998) .
In an age-and sex-stratified population-based sample of a normal population living in South Germany (n ¼ 415, 206 women and 209 men, ranging from 50 to 80 y), serum 25OHD reached its nadir of 42.5722.5 nmol/l in January, and its zenith of 67.5725 nmol/l in the months August and September (Scharla et al, 1996) . Of the women, 40% had a subclinical vitamin D deficiency in winter, defined as o 30 nmol/l 25OHD (Scharla, 1998) . The serum 25OHD concentration of elderly subjects living in Belgium, who were consecutively admitted to one of the geriatric wards in Leuven (n ¼ 240, 137 women and 103 men, ranging from 55 to 99 y), reached its nadir of 18 nmol/l in February. The lowest levels were recorded in the 4 months from January to April (mean o 25 nmol/l), and its zenith of 30 nmol/l in July (Bouillon et al, 1987) . It was found that the frequency of very low levels of 25OHD (o 12.5 nmol/l) was more pronounced in wheelchair-bound or institutionalized elderly subjects (Bouillon et al, 1987) . From these reports, it could be concluded that the unhealthy elderly living in Belgium had lower 25OHD levels in winter than in summer. Their monthly and yearly 25OHD levels were significantly lower than those of their healthy younger control subjects. The unhealthy elderly living in Belgium also had lower monthly 25OHD levels than the healthy elderly living in South Germany. Not only in unhealthy elderly, but also in young subjects a significant difference between winter and summer 25OHD has been found (Guillemant et al, 1995 (Guillemant et al, , 1999 Docio et al, 1998; Zittermann et al, 1999) . Taken together, these results emphasize a widespread seasonal variation in 25OHD levels, with low 25OHD levels in winter. This seasonal variation is reflected in the approximate normal range for serum 25OHD values 25-130 nmol/l. This wide range is used to classify individuals in vitamin D deficient and sufficient.
The Royal Dutch Meteorological Institute (KNMI) publishes the monthly and yearly mean duration of sunlight in hours of different cities in the world (Nellestijn & Dekker, 1998) . The monthly mean duration of sunlight in hours in Munich in south Germany (48:211 NL, alt. 527 m) and Brussels in Belgium (50:541 NL, alt. 55 m) published by Nellestijn and Dekker (1998) , as well as the monthly mean serum 25OHD concentration of healthy elderly in south Germany reported by Scharla (1998) and that of unhealthy elderly in Belgium reported by Bouillon et al (1987) , were used to calculate the correlations. The author of the present paper compared 12 consecutive months of the year and found a significant correlation between sunlight and 25OHD, 2 months later, in healthy elderly in south Germany r ¼ 0.86 (Po 0.001, n ¼ 12) and in unhealthy elderly in Belgium r ¼ 0.90 (Po 0.001, n ¼ 12). This finding is in line with the time lag of 2 months between sunlight and 25OHD reported in other studies (Hine & Roberts, 1994; Need et al, 2000) . It has been stated that the concentration as found in healthy individuals at the end of summer or as found in healthy individuals in the tropics provides a physiological indication of what might be optimal to maintain throughout the year (Vieth, 1999) .
The approximate normal range for serum 1,25-(OH) 2 D values is 36-144 pmol/l (Feldman et al, 1997) . No seasonal variation in 1,25-(OH) 2 D levels was observed in healthy adults (Chesney et al, 1981; Bouillon et al, 1987) . No association between 25OHD and concentrations of 1,25-(OH) 2 D was found in euthyroid patients, who previously had low 25OHD (o50 nmol/l) levels, but had been advised to take 25 mg (1000 IU)/day vitamin D 3 (Vieth et al, 2003) .
Vitamin D nutrition
Dietary compensation should occur to overcome low 25OHD levels when cutaneous production of vitamin D 3 is inadequate. For their recommendations of vitamin D 3 intake, National Councils on Food and Nutrition have abandoned the older criterion of absence of disease as the definition of adequacy. Now they are confronted with two new questions, one: what concentration of serum 25OHD is adequate, and two: how much vitamin D 3 is needed each day to meet or sustain that concentration. The border between a vitamin D-deficient and -sufficient state is represented by reported cutoff levels for the 25OHD concentration which rang widely from 12.5 to 140 nmol/l, but seem to increase over the years (Bouillon et al, 1987; Chapuy et al, 1997; DawsonHughes et al, 1997; Barger-Lux et al, 1998; Malabanan et al, 1998; Scharla, 1998; Thomas et al, 1998; Vieth, 1999; Need et al, 2000; Lips, 2001; Heaney et al, 2003a) . Serum levels of 25OHD between 30 and 100 nmol/l have been mentioned as necessary to ensure vitamin D sufficiency (Barger-Lux et al, 1998; Lips, 2001; Heaney, 2003b; Vieth et al, 2003) . In elderly nursing home residents, vitamin D 3 10 mg (400 IU)/day increased serum 25OHD from 22 to 62 nmol/l in 12 weeks (Chel et al, 1998) . Others have observed higher doses to ensure adequate serum 25OHD levels (Barger-Lux et al, 1998; Heaney et al, 2003a; Vieth et al, 2003) . Recently, a daily supplement of 25 mg (1000 IU) vitamin D 3 has been advocated for all adults to ensure a serum 25OHD level of at least 40 nmol/l (Vieth et al, 2001 (Vieth et al, , 2003 . There is no consensus on this, but this dose is well below the Tolerable Upper Intake Level ( 
MS and vitamin D
MS prevalence and sunlight MS is more common in temperate climates than in the tropics, with a prevalence of 100/100 000 and 10/100 000, respectively (Martyn, 1991; Gale & Martyn, 1995) . Of all the climatic variables analyzed, insolation, in terms of annual and winter hours of sunlight, exhibited the strongest negative correlation with the prevalence of MS (Acheson et al, 1960; Norman et al, 1983) . The incidence of MS is low in areas with at least 3000 h sunlight annually or with sufficient vitamin D 3 intake (Goldberg, 1974a) . Unlike mortality from skin cancer, mortality from MS was negatively associated with residential exposure to sunlight (Freedman et al, 2000) . A negative correlation between ultraviolet radiation (UVR) and MS prevalence was found in Australia ( Van der Mei et al, 2001) . The suggestion that the risk of developing MS is largely determined before the age of 15 y has been questioned by Australian epidemiological data. The prevalence in the migrant population from the UK and Ireland in the different regions in Australia showed a significant correlation with latitude and was considerably less than in their countries of origin (Hammond et al, 2000) . The epidemiological evidence suggests that UVR may play a protective role in three autoimmune diseases: MS, insulindependent diabetes mellitus, and rheumatoid arthritis has been reviewed (Ponsonby et al, 2002) . New evidence has been reported that increased sun exposure during ages 6-15 y is associated with a decreased risk of multiple sclerosis (Van der Mei et al, 2003) . Interestingly, the prevalence of MS among Sardinians presents evidence against the latitude gradient theory (Pugliatti et al, 2001 ) and could be explained by a high susceptibility of the population to MS (Montomoli et al, 2002) .
MS and 25OHD serum concentration
Only a few reports have investigated the association between MS and 25OHD serum concentration. Vitamin D deficiency was detected in a group of female MS patients who were subjects of a study on osteoporosis. Of these patients (n ¼ 52), 70% had a subclinical vitamin D deficiency, defined as serum 25OHD o50 nmol/l (Nieves et al, 1994) . This study consecutively recruited female MS patients who were admitted to a tertiary care hospital because of deterioration in their clinical status, and there was no appropriate control group. Results suggested that low circulating 25OHD levels contributed to low bone mineral density (BMD) (Nieves et al, 1994) .
Another group of MS patients (n ¼ 54), of whom 64% had a subclinical vitamin D deficiency, defined as serum 25OHD o 50 nmol/l, had more rapid bone loss and more frequent fractures than healthy age-and gender-matched controls (Cosman et al, 1998) . Levels of 25OHD were on average 20-37.5 nmol/l lower in MS patients than they were in the three control groups: men, pre-and postmenopausal women. In the analyses, lack of sunlight exposure, a vitamin D-deficient diet, immobility, and corticosteroid treatment contributed to the low 25OHD serum concentrations (Cosman et al, 1998) . However, in this study, it was not clear whether the vitamin D deficiency was merely a result of immobility, as it has been reported that immobility may be the strongest risk factor for vitamin D deficiency (Gloth et al, 1995) . Mahon et al (2003) reported that 48% of MS patients (n ¼ 39) had a subclinical vitamin D deficiency at baseline, defined as serum 25OHD o50 nmol/l.
No reports have been found on the 1,25-(OH) 2 D serum concentration in MS patients. Case-control studies with sufficient power on patients with MS with respect to serum 25OHD and 1,25-(OH) 2 D concentration are lacking. Moreover, seasonal variation of 25OHD serum concentration has not yet been established in MS patients.
MRI and season
Various studies have investigated the association between number of active magnetic resonance imaging (MRI) lesions and season (Auer et al, 2000; Embry et al, 2000; Rovaris et al, 2001; Killestein et al, 2002) . Active MRI lesions are the gadolinium-enhancing lesions on MRI scans, which reflect subclinical disease activity. A statistical significant seasonal fluctuation, measured as active MRI lesions, has been demonstrated in MS patients (n ¼ 53) living in south Germany. The number of active MRI lesions was the highest in April and lowest in October (Auer et al, 2000) . The seasonal variation of active MRI lesions in MS patients has since been re-addressed in other studies. The monthly mean number of MRI lesions was pooled in four seasons: spring (March, April, May), summer (June, July, August), autumn (September, October, November), and winter (December, January, February). No statistical significant difference could be detected between the number of active MRI lesions in these four seasons (Rovaris et al, 2001; Killestein et al, 2002) . However, these calendar months do not necessarily correspond with the 'vitamin D winter' and more importantly do not necessarily represent the circulating 25OHD levels of the individuals under investigation. In addition, Rovaris et al (2001) used data from MS patients living in different parts of the world. Embry et al (2000) have graphically combined two separate studies and showed close correspondence between the curve representing monthly mean serum 25OHD concentrations in the group of non-MS individuals provided by Scharla and the curve representing the monthly number of MRI lesions, 2 months later, in MS patients provided by Auer (Scharla, 1998; Auer et al, 2000) . Of course, there exists an inherent weakness in combining data from different studies to reach a new conclusion. In this case, the 25OHD serum levels were measured in a group of non-MS individuals. These levels may not be representative of a cohort of MS patients, whose vitamin D metabolite levels may be influenced by their MS.
The monthly mean duration of sunlight in hours in Munich published by Nellestijn and Dekker (1998) and the monthly mean number of active MRI lesions reported by Auer et al (2000) were used to calculate the correlation. The author of the present paper compared the 12 consecutive months of the year and found a statistical significant inverse correlation between sunlight and active MRI lesions, 4 months later, r ¼ À0.90 (Po0.001, n ¼ 12).
Further research is required; currently no reports are available on mean serum 25OHD concentrations, and active MRI lesions by months of the year in patients with MS living in the same area.
MS and vitamin D-related genetic polymorphism
Genetic factors may contribute to the disease course in MS patients (Goldberg, 1974a, b; Hayes et al, 1997) . Vitamin D receptor gene (VDRG) polymorphism could be a factor in determining susceptibility to MS or disease modulation of MS. An association with MS for VDRG polymorphism or linkage disequilibrium of VDRG to other pathologic gene loci has been found among Japanese women (Fukazawa et al, 1999) . In another Japanese study, DBP polymorphism showed no differences in distribution between MS patients and non-related healthy individuals (Niino et al, 2002) . In a Canadian population, no evidence was found for association or linkage of genes involved in the metabolism and function of vitamin D with MS, including the 1a-OHase gene, the DBP gene, and the VDR gene (Steckley et al, 2000) .
Neuro-immunology and vitamin D metabolites
The CNS as a target tissue for vitamin D metabolites is supported by discovery of VDR in the rat forebrain, hippocampus, cerebellum, brainstem, spinal cord, and perivascular tissue and the discovery of 1a-OHase in cerebellum and cerebral cortex (Neveu et al, 1994 , Issa et al, 1998 , Hewison et al, 2000 Zehnder et al, 2001) . In addition, the possibility of a local synthesis of 1,25-(OH) 2 D in brain has been postulated (Garcion et al, 2002) . Profound alterations in the brain at birth have been demonstrated in rats born to vitamin D 3 -deficient mothers (Eyles et al, 2003) .
The influences of 1,25-(OH) 2 D on cells of the nervous system were recently reviewed by Garcion (Garcion et al, 2002) . It appeared that 1,25-(OH) 2 D had effects on neurons, oligodendrocytes, as well as astrocytes, but the exact pathways of these effects remain to be established. In general, the influences of 1,25-(OH) 2 D on these cells seem to be neuroprotective and anti-inflammatory (Garcion et al, 2002) .
Immune system and 1,25-(OH) 2 D The active form of vitamin D, 1,25-(OH) 2 D, is a potent regulator of the immune system Casteels et al, 1995; Cantorna et al, 1996 Cantorna et al, , 1998 Cantorna et al, , 1999 Hayes et al, 1997; Nashold et al, 2000 Nashold et al, , 2001 Gregori et al, 2001; Griffin et al, 2001 ). Here we focus on the autoimmune animal model for MS EAE. The preventive and curative effects of vitamin D-related treatment on the clinical course of EAE are described (Table 1 ). The effects on the cellular level, which are relevant for EAE, and may have implications for MS and other autoimmune diseases, are summarized. The possible actions of vitamin D metabolites on immune cells relevant for EAE are portrayed in Figure 2 . Finally, the influences of vitamin D metabolites on the production of cytokines and nitric oxide (NO), and on the BBB are described.
Experimental autoimmune encephalomyelitis (EAE)
EAE is a useful (although not perfect) animal model of human MS (Van Etten et al, 2003) . EAE is induced by immunization of rodents or primates with myelin or myelin components. This results in the generation of autoreactive, myelin-specific T lymphocytes. In the CNS of EAE animals perivascular inflammatory lesions are present and, depending on the immunization protocol, a variable degree of demyelination is observed. The lesions in the brain and spinal cord are accompanied by transient clinical signs such as paralysis of the tail and hind limbs. EAE can also be induced by transferring T lymphocytes from rats immunized with myelin components into naïve rats, indicating the crucial role of T lymphocytes in this model (Paterson & Hanson, 1969) . In particular, the interferon-gamma (IFN-g)-producing T helper 1 (Th1) lymphocytes are required for induction of EAE. Macrophages are crucial for the effector phase of EAE, the phase in which actual tissue damage is caused by an immune response. In EAE, macrophage depletion leads to complete suppression of clinical signs (Huitinga et al, 1990; Tran et al, 1998) . Table 1 summarizes the observed effects of vitamin D-related treatment on EAE. Exposure of mice to whole body (full spectrum) UV was effective in preventing EAE when administered before immunization, but was ineffective in modifying ongoing EAE or in preventing relapses of EAE induced by re-immunization (Hauser et al, 1984) . However, this report does not mention vitamin D metabolites at all. The first study on 1,25-(OH) 2 D treatment of EAE was by Lemire and Archer (1991) and showed that administration of 1,25-(OH) 2 D during the immunization phase in mice significantly prevented the onset and development of EAE. The preventive effect of 1,25-(OH) 2 D on EAE in mice given before EAE induction was complete (Cantorna et al, 1996) . When treatment with 1,25-(OH) 2 D on EAE was started after the appearance of clinical signs, progression and severity was decreased in mice (Cantorna et al, 1996) and rats (Nataf et al, 1996) . A vitamin D-deficient diet resulted in an increased susceptibility to EAE, an accelerated onset of paralytic symptoms and aggravated clinical symptoms (Cantorna et al, 1996) . In rats deprived of vitamin D, the clinical signs of EAE increased (Garcion et al, 2003) . Withdrawal of 1,25-(OH) 2 D after EAE induction resulted in a resumption of clinical signs (Cantorna et al, 1996) . The effect of 1,25-(OH) 2 D can be potentiated by cyclosporine, sirolimus (Rapamycin, RAP), and calcium (Branisteanu et al, 1995 (Branisteanu et al, , 1997 Cantorna et al, 1999) . In EAE in mice, calcium was required in addition to 1,25-(OH) 2 D to prevent the appearance of this disease, and the higher the calcium intake the lower the 1,25-(OH) 2 D dose needed (Cantorna et al, 1999) . These results suggest that 1,25-(OH) 2 D and dietary calcium are both involved in the prevention of symptomatic EAE (Cantorna et al, 1999; DeLuca & Cantorna, 2001 ). Interestingly, changes in dietary calcium and phosphate levels resulted in changes in target tissue VDR expression (Issa et al, 1998) . VDR itself is essential for the immunosuppressive ability of 1,25-(OH) 2 D during EAE (Meehan & DeLuca, 2002) . From studies on vitamin D deficiency in the elderly, it is understood that a low calcium intake causes secondary hyperparathyroidism, which increases vitamin D turnover and aggravates vitamin D deficiency and its consequences, while high calcium intake may reduce vitamin D requirement (Lips, 2001) .
EAE and vitamin D-related treatment
Treatment with synthetic 1,25-(OH) 2 D analogs has also been reported (Lemire et al, 1994; Mattner et al, 2000; Van Etten et al, 2000 Garcion et al, 2003) . Curative treatment of vitamin D-deprived rats with the nontoxic-1,25-(OH) 2 D analog MC1288 strongly inhibited EAE symptoms, thus suggesting that these compounds may be a suitable treatment for MS (Garcion et al, 2003) . The 1,25- (OH) 2 D analog TX527 decreased disease severity and postponed onset in mice with EAE, and adding the bisphosphonate pamidronate prevented the side effects of this analog (Van Etten et al, 2003) .
Cellular effects
T lymphocytes and dendritic cells. The effect of 1,25-(OH) 2 D on the acquired, antigen-specific immune response is initiated by exposure of antigen in the groove of MHC class II molecules to T lymphocytes. This so-called antigen presentation results in proliferation and cytokine production by antigen-specific T lymphocytes. Based on the cytokine production profile, two populations of T lymphocytes can be distinguished. Th1 cells produce IFN-g, a pro-inflammatory cytokine that promotes macrophage activation and MHC class II expression. T helper 2 (Th2) cells produce interleukin (IL)-4 and IL-5, promoting antibody production in particular IgE. Antigen-presenting cells can influence the cytokine production profile of T lymphocytes upon antigen recognition. By production of the cytokine IL-12, antigen-presenting cells can induce a shift towards the Th1 cytokine profile. Classical antigen-presenting cells are the so-called dendritic cells, which are derived from monocytes. They occur in almost all tissues of the body and in large numbers in lymphoid organs where they present antigen to T lymphocytes. 1,25-(OH) 2 D inhibits antigen-induced T-lymphocyte proliferation (Bhalla et al, 1984; Lemire & Adams, 1992) and prevents Th1 development in EAE (Mattner et al, 2000) . Various reports have shown that 1,25-(OH) 2 D exerts major effects on dendritic cells (DC), by inhibition of DC maturation (Penna & Adorini, 2000; Griffin et al, 2001) . Accordingly, DC of VDR-deficient mice fail to respond to maturational stimuli (Griffin et al, 2001) . Mature DC are required for the induction of an efficient Th1 response, in particular by their production of the pro-inflammatory cytokine IL-12. The production of IL-12 by DC is downregulated by 1,25-(OH) 2 D, whereas the production of the anti-inflammatory cytokines IL-10 is enhanced (Penna & Adorini, 2000) and the production of TGF-b is unaffected (Griffin et al, 2001 Garcion et al (2002) . The effect of 1,25-(OH) 2 D on the cells of the BBB is unknown, but EAE data suggest that cellular infiltration is inhibited (Nashold et al, 2000) . Further references on which this figure is based are mentioned in the text under Neuro-immunology and vitamin D metabolites. Dendritic cell, DC; monocyte, MO; T helper 1 lymphocyte, Th1; T helper 2 lymphocyte, Th2; interferon gamma, IFNg; interleukin, IL; nitric oxide, NO; transforming growth factor b, TGFb; tumor necrosis factor alpha, TNFa.
the generation of a population of CD4 þ CD25-regulatory T cells (Gregori et al, 2001 ). The potency of this effect of 1,25-(OH) 2 D is illustrated by the fact that tolerance is induced by 1,25-(OH) 2 D/MMF treatment to fully mismatched pancreatic islet allografts in mice (Gregori et al, 2001) . Altogether, these data show that 1,25-(OH) 2 D inhibits DC maturation and inhibits the induction of pro-inflammatory Th1 cells. In addition, the formation of tolerogenic T cells, an active mechanism for natural immune suppression, and the production of anti-inflammatory cytokine IL-10 are promoted by 1,25-(OH) 2 D.
Macrophages. In addition to its effect on T lymphocytes, the effect of 1,25-(OH) 2 D on macrophages contributes to its immunomodulatory potential. Almost two decades ago, it has been reported that 1,25-(OH) 2 D promoted the induction of (pro)monocytic differentiation to macrophages (Koeffler et al, 1984) . 1,25-(OH) 2 D increases the antigen-presenting activity of macrophages and enhances the phagocytic activity of macrophages (Goldman, 1984; Amento & Cotter, 1988) .
Cytokines and nitric oxide (NO)
The cellular effects of 1,25-(OH) 2 D include effects on production of immunoregulatory molecules such as cytokines and NO. 1,25-(OH) 2 D decreases the production of proinflammatory cytokines IL-2, IFN-g and TNF-a in vitro and in vivo (Manolagas et al, 1985; Reichel et al, 1989; Lemire & Adams, 1992) , and IL-12 in vivo (Lemire et al, 1994; D'Ambrosio et al, 1998; Mattner et al, 2000) . On the other hand, it promotes the in vivo production of anti-inflammatory cytokines such as IL-4 and TGF-b (Cantorna et al, 1998 ). An increase of TGF-b1 expression in lymph nodes at the periphery may explain the beneficial effect of 1,25-(OH) 2 D in EAE and has been re-emphasized in MS (Cantorna et al, 1998; Mahon et al, 2003) . In contrast, TGF-b1 increase was not found in the rat CNS (Garcion et al, 2003) , suggesting that the effects of 1,25-(OH) 2 D in EAE are due to effects on the peripheral immune system rather than on local immune suppression. 1,25-(OH) 2 D triggers the production of inducible nitric oxide synthase (iNOS) by a human macrophage cell line in vitro (Figure 2) (Rockett et al, 1998) , but decreases iNOS expression during rat EAE (Garcion et al, 1997 (Garcion et al, , 1998 (Garcion et al, , 2003 . The macrophage enzyme iNOS is required for the inducible production of NO by macrophages. The role of NO in EAE and MS is not yet fully clarified, but several studies indicate a worsening effect due to NO production in the brain (Cross et al, 1994 (Cross et al, , 2000 Zhao et al, 1996) . Others indicate that NO has an immune-downregulating effect in EAE (Ruuls et al, 1996; Willenborg et al, 1999) .
Blood-brain barrier (BBB)
Inflammatory cells can only cause damage in the CNS after they have migrated from the peripheral blood into the CNS parenchyma. This involves passage of these cells across the BBB. A direct effect of 1,25-(OH) 2 D on the BBB has, to our knowledge, not been described thus far. In 1,25-(OH) 2 Dtreated EAE rats, a reduced number of infiltrated macrophages in the CNS was observed (Nataf et al, 1996 , Nashold et al, 2000 , suggesting that 1,25-(OH) 2 D suppresses the transendothelial migration of monocytes (Nashold et al, 2000) .
MS and vitamin D supplementation
Only few reports are available on the effect of vitamin D supplementation in MS patients. A group of MS patients (n ¼ 16) was treated with dietary supplements containing vitamin D 125 mg (5000 IU), calcium (16 mg/kg/day), and magnesium (10 mg/kg/day) (Goldberg et al, 1986) . The results after 1 y showed that exacerbations were not eliminated, but their number was reduced by 59% compared with the number of the previous year(s). Vitamin D was given in the form of cod liver oil (20 g/day). Apart from vitamin D, cod liver oil may contain vitamin A and the amount of vitamin A in cod liver oil 20 g/day is six times its toxic dose. The limited number of patients in this study and the methodological bias (six out of 16 patients dropped out) do not allow conclusions. Mahon et al (2003) studied the cytokine profile in patients with MS following 6 months supplementation with calcium 800 mg/day and vitamin D 25 mg (1000 IU)/day (n ¼ 17) or calcium 800 mg/day and placebo (n ¼ 22). The serum 25OHD levels in the vitamin D treatment group significantly increased from 42.5715 to 70720 nmol/l. Vitamin D supplementation also significantly increased serum TGF-b1 levels.
Double-blind randomized placebo-controlled studies on vitamin D supplementation in patients with MS with sufficient power are lacking.
Future prospects: MS and 1,25-(OH) 2 D treatment
Given its immune-modulatory and anti-inflammatory effects, treatment with 1,25-(OH) 2 D, or its analogs, may be valuable in the management of MS (Cantorna et al, 1996; Hayes et al, 1997; Verstuyf et al, 1998; Mathieu et al, 2001; Mathieu & Adorini, 2002) . The calcemic side effects of 1,25-(OH) 2 D make its use in high doses, needed for immunomodulation, unattractive. 1,25-(OH) 2 D analogs, which might block MS without affecting the blood calcium level, have been identified and synthesized . Until now, only one of these 1,25-(OH) 2 D analogs, 19-nor-1,25-dihydroxyvitamin D 2 (19-nor), was given in an oral dose for more than 9 months to 11 newly diagnosed MS patients with RRMS. This analog, however, did not reduce the number of active MRI lesions (Flemming et al, 2000) . More research and clinical trials are needed to assess the usefulness of vitamin D compounds for the treatment of MS.
Conclusion
This review provides some epidemiological and ecological evidence for the preventive role that vitamin D nutrition may play in decreasing susceptibility to MS. The putative preventive effect of adequate supply of vitamin D 3 is supported by results obtained in EAE. In EAE 1,25-(OH) 2 D prevents the onset when administered before EAE induction and ameliorates the severity and duration of EAE when given after EAE induction (Table 1) .
Widespread seasonal variation in serum 25OHD levels has been reported especially in temperate climates, with low 25OHD levels in winter. A vitamin D-deficient diet in mice and rats resulted in an increased susceptibility to EAE, and 1,25-(OH) 2 D deprivation aggravated the clinical signs of EAE (Cantorna et al, 1996; Garcion et al, 2003) . Likewise, once MS is apparent, low 25OHD levels may aggravate its severity. Living in a temperate climate may cause annually recurring seasonal low serum 25OHD concentrations in MS patients. Low serum 25OHD concentrations may be responsible for upsetting the balance in the neuro-immune system of MS patients, causing reversible and irreversible neuro-immunological damage aggravating RRMS. The cumulative negative effects over the years may contribute to the secondary progressive course of MS. Further studies are required to establish the seasonal fluctuations in serum concentrations of vitamin D metabolites in MS patients. The effects of sunlight on the clinical manifestations of MS may be influenced by the fact that this may not be a direct effect, but indirect. There might be a time lag of 2 months between sunlight and 25OHD and a time lag of 4 months between sunlight and MRI lesions. A 25OHD reference interval may need to be determined to distinguish inadequate from adequate levels. The quantitative relation between vitamin D 3 input and the resulting serum 25OHD concentration needs to be investigated, as it has been speculated that patients with MS may have a higher vitamin D requirement (Goldberg, 1974a; Cantorna et al, 1996; Hayes et al, 1997; Hayes, 2000; Vieth, 1999; DeLuca & Cantorna, 2001; Holick, 2002; Mahon et al, 2003) . More research is also needed to address the question if MS might be aggravated by a vitamin D-related metabolic or genetic disorder. It is hypothesized that vitamin D deficiency might only lead to MS in susceptible individuals, and a poor vitamin D status might expose an unknown, possibly gene-related, etiology.
Finally, we need to answer the question: 'Do we need 1,25-(OH) 2 D analogs for the treatment of MS, as pharmacological doses of 1,25-(OH) 2 D are accompanied by adverse side effects, or is it simply a matter of enough vitamin D 3 all year round and enough time for it to take effect?' Until more evidence is provided, it is suggested that MS patients living in temperate climates should have their serum 25OHD concentration checked in winter, JanuaryMarch in the northern and July-September in the southern hemisphere, respectively, or use a vitamin D 3 supplement and follow the recommendations for vitamin D 3 and calcium published by their National Council on Food and Medicine, 1997; SCF, 2002; Heaney et al, 2003a) . Alternatively, the reader is referred to the most recent recommendations for the required daily intake of vitamin D 3 and calcium given for bone loss, osteoporosis, and fractures (Chapuy et al, 1992; Lips, 2001) . For the moment, it would be wise to aim at a serum 25OHD level 450 nmol/l either by augmenting sunlight exposure or by a vitamin D 3 supplement of 10 mg (400 IU) per day. Such a dose is safe, and side effects are virtually nonexistent (Lips, 2001) . Further studies should be done to evaluate if higher levels of 25OHD are necessary in the management of MS to prevent exacerbations. In contrast, the use of the active metabolite 1,25-(OH) 2 D carries the danger of hypercalcemia, hypercalciuria, and renal failure, and should be restricted to clinical investigational use under close supervision.
